Translating Causation To Treatment - Reviewing The Microbiome's Role In Drug Development
Advancing Standards For Translational Microbiome Research In Therapeutic Development
As the vast quantity of microbiome research continues to be translated into therapeutic, biomarker and diagnostic applications, the development of standard operating procedures continues to be crucial to ensure the reproducibility and regulatory approval of these products. The purpose of this theme will be to review the importance of creating standards to ensure the long-term viability of microbiome-based products within the pharmaceutical industry to allow for greater comparability and reproducibility between studies without dampening cutting edge scientific innovation.
8.30
Introducing the Microbiome Therapeutics Innovation Group – Building a Collective Voice to Enhance the Regulatory, Investment and Commercial Success of Microbiome-Based Therapeutics
Thomas J. DesRosier
Chief Legal Officer & Secretary
Seres Therapeutics
9.00
Improving Microbiome Work Flow Standards To Overcome Regulatory Hurdles And Accelerate Product Development
Representative from NIST invited. More details to be announced after Government Shutdown
9.30
Panel Discussion - Developing Industry Standards For The Microbiome-Based Therapeutics
Panellists to be Confirmed Shortly - Please Check Back with Us Soon
10.00
Powering Microbiome Discovery With Big Data
Dan Knights
Chief Executive Officer
CoreBiome
10.30
Morning Refreshments and Speed Networking
STREAM A: DISCOVERY PLATFORMS &
PRE-CLINICAL DEVELOPMENT OF
MICROBIOME-BASED THERAPEUTICS
STREAM B: MANUFACTURING, CLINICAL
DEVELOPMENT & COMMERCIALIZATION OF
MICROBIOME-BASED THERAPEUTICS
STREAM C: MICRONIOME BIOMARKERS, BIONFORMATICS & THERAPEUTIC RESPONSE
SUBTRACTIVE MICROBIOME APPROACHES DISCOVERY & DEVELOPMENT
DEVELOPMENT
MEASURING THE IMPORTANCE OF
ENGRAFTMENT FOR MICROBIOME-BASED THERAPEUTICS
USING ARTIFICIAL INTELLIGENCE TO TACKLE
THE COMPLEXITY OF MICROBIOME DATA
Dat
11.30 - Immunotherapeutic Approaches to Selective Modulation of Microbiomes
Julius Goepp
Chief Executive Officer
Translational Medicine in Immunology
Scaled Microbiomics
12.00 - Customized Phage Therapies for Chronic Disease
Assaf Oron
Chief Business Officer
BiomX
11.30 - An Exclusive Metabolic Niche Enables Strain Engraftment in the Gut Microbiota
Liz Shepherd
Co-Founder
Novome Biotechnologies
11.30 - Incorporating Microbiome and Clinical Data to Develop Predictive Algorithms as a Marker of Response to IBD Treatment
Ashwin Ananthakrishnan MD
Associate Professor of Medicine
Massachusetts General Hospital
12.00 - Combining Genomic, Metabolomic Data with Machine Learning to Identify New Targets from the Human Microbiome
Nathan Magarvey
Founder
Adapsyn Bioscience
GENETICALLY ENGINEERED BACTERIA DISCOVERY & DEVELOPMENT
DEVELOPMENT
PHARMACEUTICAL PERSPECTIVES & PARTNERSHIP STRATEGIES FOR MICROBIOME-BASED THERAPEUTICS
12.30 - A Prototype Biomarker for Microbiome Rehabilitation in Patients with Clostridium Difficile Infections: Application to a Clinical Trial of a Lyophilized, Non-Frozen, Oral, Microbiota-Based Drug rbx7455
Ken Blount
Chief Scientific Officer
Rebiotix
12.30 - Development of a Novel IBD Therapeutic Using Engineered Clostridium
Ben Bradley,
Head of Partnerships & Licensing
CHAIN Biotech
12.00 - Panel Discussion – New Perspectives On Pharmaceutical & Biotech Partnerships In The Microbiome
Mark Smith
Chief Executive Officer
Finch Therapeutics Group
Mike Romanos
Chief Executive Officer
Microbiotica
Henry Rath
SVP Corporate Development
Seres Therapeutics
13.00 - Presentation Title TBC, Please Check back With us Soon
Helena Cowley
CEO
Captozyme
13.00
Lunch and Networking
14.50 - Engineering Therapeutic Bacteria to Robustly Colonize the Gut
Wes Whitaker,
Co-Founder and CEO
Novome Biotechnologies
CLINICAL DESIGN & DEVELOPMENT CONTINUED
USING ARTIFICIAL INTELLIGENCE TO TACKLE THE COMPLEXITY OF MICROBIOME DATA
GENERATING & TRANSLATING ANIMAL STUDIES TO HUMANS
14.50 - Clinical Trial Design Challenges & Considerations for a Novel Synbiotic in Patients with Type 2 Diabetes
Colleen Cutcliffe
Co-Founder & Chief Executive Officer
Whole Biome
14.50 - Biomarker and Bioinformatic Rationale for Microbiome Drug Development in Cancer
Jennifer Wortman
Senior Director, Bioinformatics
Seres Therapeutics
15.20 - Panel Discussion - Exploring the Utility of In-Vivo Models for Translational Microbiome Research
Esi Lamouse-Smith
Director Early Development Translational Medicine in Immunology
Janssen Pharmaceuticals
Lynn Bry MD
Director
Massachusetts Host-Microbiome Center
GENERATING & TRANSLATING ANIMAL STUDIES TO HUMANS
15.20 - Matrisys Bio – Phase 2 Clinical Updates and New Developments
Mark Wilson
President & Chief Executive Officer
MatriSys Bioscience
15.50 - The Human Microbiome and IBS
Mark Pimentel MD
Director of MAST Program
Cedars-Sinai
16.20 - Standardising the Process of Clinical Trial Design and Capsule Development for Microbiome-Based Therapeutics
Alexander Khoruts MD
Medical Director
University of Minnesota Microbiota Therapeutics/span>
15.20 - Panel Discussion: Reviewing the Role of the Human Microbiome in Biomarker Discovery & Development
Jennifer Wortman
Senior Director, Bioinformatics
Seres Therapeutics
Matthew Henn
EVP Microbiome R&D
Seres Therapeutics
Gerard Honig
Translational Research Manager
Crohn’s & Colitis Foundation
Glennda Smithson
Director, Translational Biomarker Research (Immunology)
Takeda
MICROBIOME LEADERS OF TOMORROW – LATE BREAKING ABSTRACTS
16.20 - Standardising the Process of Clinical Trial Design and Capsule Development for Microbiome-Based Therapeutics
Alexander Khoruts MD
Medical Director
University of Minnesota Microbiota Therapeutics/span>
CHALLENGES IN MICROBIOME BIOINFORMATICS & DATA INTEGRATION
15.50 - Actobiotics®, Lactococcus-Based Biopharmaceuticals for Expression and Local Delivery of Therapeutics at Target Sites
Lothar Steidler
Chief Technology Officer
ActoBio Therapeutics
16.05 - Harnessing Whole Community Microbiome Transfer to Develop and Advance Novel Medicinal Products
James McIlroy
Founder & Chief Business Office
Enterobiotix
16.20 - Obtaining Hidden & Novel Small Molecules of the Microbiome
Ross Youngs
CEO
Biosortia Pharmaceuticals
16.35 - Presentation Title TBC, Please Check Back With us Soon
15.50 - Bioinformatic Analysis of Microbial Communities for Novel LBP Discovery
Daniel van der Lelie
Chief Scientific Officer
Gusto Global
16.20 - Understanding Precision Metagnomics to Assess Human Biology, Disease and Diagnostics
Rita Colwell
Distinguished University Professor
University of Maryland
16.50
Close of 4th Microbiome Movement - Drug Development Summit 2019